Circulating/VBG
HOTAIR/NN
LncRNA/NN
Is/VBZ
Potentially/RB
Up-regulated/JJ
in/IN
Coronary/NN
Artery/NN
Disease/NN
./.
====================
Coronary/NN
artery/NN
disease/NN
(/(
CAD/NN
)/)
is/VBZ
one/CD
of/IN
the/DT
leading/VBG
causes/VBZ
of/IN
death/NN
and/CC
disability/NN
all/DT
around/IN
the/DT
world/NN
./.
====================
Recent/JJ
studies/NNS
have/VBP
revealed/VBN
that/IN
aberrantly/RB
regulated/VBN
long/JJ
non-coding/JJ
RNA/NN
(/(
lncRNA/NN
)/)
as/IN
one/CD
of/IN
the/DT
main/JJ
classes/NNS
of/IN
cellular/JJ
transcript/NN
plays/VBZ
a/DT
key/JJ
regulatory/JJ
role/NN
in/IN
transcriptional/JJ
and/CC
epigenetic/JJ
pathways/NNS
./.
====================
Recent/JJ
reports/NNS
have/VBP
demonstrated/VBN
that/IN
circulating/VBG
lncRNAs/NNS
in/IN
the/DT
blood/NN
can/MD
be/VB
potential/JJ
biomarkers/NNS
for/IN
CAD/NN
./.
====================
HOTAIR/NN
is/VBZ
one/CD
of/IN
the/DT
most/JJS
cited/VBN
lncRNAs/NNS
with/IN
a/DT
critical/JJ
role/NN
in/IN
the/DT
initiation/NN
and/CC
progression/NN
of/IN
the/DT
gene/NN
expression/NN
regulation/NN
./.
====================
Recent/JJ
research/NN
on/IN
the/DT
role/NN
of/IN
the/DT
HOTAIR/NN
in/IN
cardiovascular/JJ
disease/NN
lays/NNS
the/DT
basis/NN
for/IN
the/DT
development/NN
of/IN
new/JJ
studies/NNS
considering/VBG
this/DT
lncRNA/NN
as/IN
a/DT
potential/JJ
biomarker/NN
and/CC
therapeutic/JJ
target/NN
in/IN
CAD/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
aimed/VBD
to/TO
compare/VB
the/DT
expression/NN
of/IN
HOTAIR/NN
lncRNA/NN
in/IN
the/DT
blood/NN
samples/NNS
of/IN
patients/NNS
with/IN
CAD/NN
and/CC
control/NN
samples/NNS
./.
====================
The/DT
expression/NN
level/NN
was/VBD
examined/VBN
by/IN
semi-quantitative/JJ
reverse/JJ
transcriptase/NN
polymerase/NN
chain/NN
reaction/NN
technique/NN
./.
====================
Our/PRP$
data/NNS
shows/VBZ
that/IN
expression/NN
of/IN
HOTAIR/NN
is/VBZ
up-regulated/VBN
in/IN
blood/NN
samples/NNS
of/IN
patients/NNS
with/IN
CAD/NN
./.
====================
Cardiovascular/JJ
disease/NN
(/(
CVD/NN
)/)
is/VBZ
one/CD
of/IN
the/DT
leading/VBG
causes/VBZ
of/IN
death/NN
in/IN
the/DT
world/NN
and/CC
include/VBP
a/DT
group/NN
of/IN
disorders/NNS
that/DT
occur/VBP
in/IN
the/DT
heart/NN
or/CC
the/DT
arteries/NNS
[/(
1/CD
]/)
./.
====================
Coronary/NN
artery/NN
disease/NN
(/(
CAD/NN
)/)
as/IN
a/DT
most/JJS
common/JJ
type/NN
is/VBZ
caused/VBN
by/IN
atherosclerosis/NN
that/DT
includes/VBZ
stable/JJ
angina/NN
,/,
unstable/JJ
angina/NN
,/,
myocardial/JJ
infarction/NN
,/,
and/CC
sudden/JJ
cardiac/JJ
death/NN
./.
====================
Atherosclerosis/NN
can/MD
be/VB
created/VBN
over/IN
time/NN
./.
====================
It/PRP
is/VBZ
considered/VBN
a/DT
high-risk/JJ
factor/NN
that/WDT
could/MD
be/VB
able/JJ
to/TO
restrict/VB
blood/NN
flow/NN
to/TO
the/DT
heart/NN
by/IN
increasing/VBG
arterial/JJ
blockage/NN
[/(
2/CD
,/,
3/CD
]/)
./.
====================
Despite/IN
survival/NN
improvement/NN
in/IN
patients/NNS
with/IN
CVD/NN
,/,
specific/JJ
diagnostic/JJ
biomarkers/NNS
have/VBP
not/RB
been/VBN
fully/RB
determined/VBN
,/,
and/CC
such/JJ
therapies/NNS
do/VBP
not/RB
fully/RB
address/VB
the/DT
underlying/VBG
cause/VBP
./.
====================
Specific/JJ
regulatory/JJ
networks/NNS
are/VBP
required/VBN
to/TO
coordinate/VB
development/NN
,/,
physiological/JJ
response/NN
,/,
and/CC
environmental/JJ
adaption/NN
of/IN
heart/NN
function/NN
that/IN
these/DT
regulatory/JJ
networks/NNS
are/VBP
composed/VBN
of/IN
pre-mediated/JJ
transcriptional/JJ
control/NN
and/CC
signaling/NN
pathway/NN
[/(
4/CD
]/)
./.
====================
More/RBR
recent/JJ
studies/NNS
have/VBP
revealed/VBN
that/IN
how/WRB
specific/JJ
physiological/JJ
and/CC
pathological/JJ
processes/NNS
possessed/VBD
by/IN
a/DT
highly/RB
diverse/JJ
group/NN
of/IN
regulatory/JJ
non-coding/JJ
RNAs/NNS
(/(
ncRNAs/NNS
)/)
through/IN
transcriptional/JJ
and/CC
epigenetic/JJ
changes/NNS
[/(
5/CD
,/,
6/CD
]/)
./.
====================
The/DT
ncRNAs/NNS
make/VBP
up/IN
the/DT
majority/NN
(/(
98/CD
%/NN
)/)
of/IN
the/DT
transcriptome/JJ
,/,
and/CC
different/JJ
classes/NNS
of/IN
this/DT
regulatory/JJ
RNA/NN
are/VBP
discovered/VBN
./.
====================
They/PRP
are/VBP
classified/VBN
based/VBN
on/IN
their/PRP$
length/NN
and/CC
function/NN
./.
====================
Long/JJ
non-coding/JJ
RNAs/NNS
(/(
lncRNAs/NNS
)/)
as/IN
a/DT
major/JJ
group/NN
of/IN
regulatory/JJ
ncRNA/NN
are/VBP
longer/RBR
than/IN
200/CD
nt/NNS
in/IN
size/NN
[/(
7/CD
,/,
8/CD
]/)
./.
====================
It/PRP
has/VBZ
been/VBN
clarified/VBN
that/DT
some/DT
lncRNAs/NNS
in/IN
the/DT
plasma/NN
were/VBD
expressed/VBN
differentially/RB
in/IN
CVDs/NNS
,/,
and/CC
aberrant/JJ
changes/NNS
of/IN
them/PRP
as/IN
a/DT
new/JJ
diagnostic/JJ
biomarker/NN
were/VBD
involved/VBN
in/IN
the/DT
development/NN
and/CC
physiological/JJ
function/NN
of/IN
heart/NN
disorders/NNS
[/(
9/CD
,/,
10/CD
]/)
./.
====================
Recent/JJ
studies/NNS
have/VBP
depicted/VBN
the/DT
important/JJ
role/NN
of/IN
HOTAIR/NN
(/(
HOX/NN
antisense/JJ
intergenic/JJ
RNA/NN
)/)
in/IN
the/DT
acute/JJ
myocardial/JJ
infarction/NN
,/,
vascular/JJ
inflammation/NN
,/,
and/CC
age-related/JJ
CVDs/NNS
but/CC
research/NN
on/IN
the/DT
role/NN
of/IN
lncRNAs/NNS
in/IN
CAD/NN
is/VBZ
still/RB
in/IN
its/PRP$
infancy/NN
[/(
11–13/CD
]/)
./.
====================
Among/IN
the/DT
lncRNAs/NNS
,/,
HOTAIR/NN
is/VBZ
an/DT
RNA/NN
that/DT
illustrates/VBZ
the/DT
importance/NN
of/IN
lncRNAs/NNS
in/IN
different/JJ
diseases/NNS
and/CC
cancers/NNS
[/(
14/CD
,/,
15/CD
]/)
./.
====================
It/PRP
is/VBZ
transcribed/VBN
from/IN
the/DT
HOXC/NN
cluster/NN
and/CC
represses/VBZ
transcription/NN
of/IN
HOXD/NN
gene/NN
as/IN
well/RB
as/IN
different/JJ
other/JJ
genes/NNS
through/IN
targeting/VBG
the/DT
histone/NN
modifications/NNS
on/IN
desired/VBN
genes/NNS
[/(
16/CD
,/,
17/CD
]/)
./.
====================
Analyzing/VBG
high-throughput/JJ
data/NNS
characterized/VBD
the/DT
expression/NN
of/IN
lncRNA/JJ
under/IN
the/DT
normal/JJ
physiological/JJ
condition/NN
as/IN
well/RB
as/IN
disease/NN
status/NN
./.
====================
It/PRP
shows/VBZ
that/IN
several/JJ
lncRNAs/NNS
are/VBP
regulated/VBN
during/IN
myocardial/JJ
infarction/NN
and/CC
heart/NN
failure/NN
while/IN
some/DT
of/IN
them/PRP
control/NN
hypertrophy/NN
[/(
18/CD
]/)
./.
====================
Different/JJ
studies/NNS
indicate/VBP
the/DT
potential/JJ
role/NN
of/IN
HOTAIR/NN
in/IN
CVDs/NNS
./.
====================
Cai/NN
et/FW
al/JJ
./.
====================
[/(
19/CD
]/)
found/VBN
a/DT
number/NN
of/IN
lncRNAs/NNS
that/DT
were/VBD
differentially/RB
expressed/VBN
in/IN
circulating/VBG
peripheral/JJ
blood/NN
monocytes/NNS
and/CC
plasma/NN
from/IN
15/CD
CAD/NN
patients/NNS
and/CC
15/CD
control/NN
subjects/NNS
./.
====================
In/IN
their/PRP$
supplementary/JJ
data/NNS
,/,
it/PRP
was/VBD
shown/VBN
that/IN
HOTAIR/NN
is/VBZ
one/CD
of/IN
the/DT
lncRNAs/NNS
that/DT
is/VBZ
up-regulated/VBN
in/IN
circulating/VBG
peripheral/JJ
blood/NN
monocytes/NNS
(/(
p/NN
=/JJ
0.0054855/CD
,/,
fold/JJ
change/NN
=/JJ
2.0744882/CD
)/)
and/CC
plasma/NN
(/(
p/NN
=/JJ
0.002561755/CD
,/,
fold/JJ
change/NN
=/JJ
8.213123/CD
)/)
in/IN
patients/NNS
with/IN
CAD/NN
compared/VBN
to/TO
non-CAD/JJ
patients/NNS
./.
====================
Based/VBN
on/IN
this/DT
,/,
we/PRP
aimed/VBD
to/TO
further/RBR
analyze/VB
the/DT
expression/NN
level/NN
of/IN
HOTAIR/NN
in/IN
patients/NNS
with/IN
CAD/NN
compared/VBN
to/TO
non-CAD/JJ
patients/NNS
by/IN
semi-quantitative/JJ
reverse/JJ
transcriptase/NN
polymerase/NN
chain/NN
reaction/NN
./.
====================
Our/PRP$
data/NNS
can/MD
provide/VB
new/JJ
evidence/NN
for/IN
the/DT
potential/JJ
role/NN
of/IN
HOTAIR/NN
in/IN
coronary/JJ
artery/NN
disease/NN
./.
====================
Clinical/JJ
samples/NNS
====================
CAD/NN
was/VBD
confirmed/VBN
by/IN
coronary/JJ
angiography/NN
./.
====================
The/DT
samples/NNS
were/VBD
composed/VBN
of/IN
20/CD
CAD/NN
patients/NNS
and/CC
20/CD
control/NN
individuals/NNS
from/IN
Imam/JJ
Khomeini/NNS
Hospital/JJ
of/IN
Ahvaz/NN
from/IN
2016/CD
to/TO
2017/CD
and/CC
sample/NN
’/CD
s/NNS
characteristics/NNS
are/VBP
provided/VBN
in/IN
Table/JJ
1/CD
./.
====================
The/DT
informed/VBN
consent/NN
was/VBD
obtained/VBN
from/IN
all/DT
subjects/NNS
./.
====================
The/DT
severity/NN
of/IN
coronary/JJ
artery/NN
narrowing/NN
estimated/VBN
by/IN
quantitative/JJ
coronary/NN
angiography/NN
to/TO
avoid/VB
inter-observer/RB
and/CC
intera-observer/RB
variability/NN
and/CC
stenosis/NN
greater/JJR
than/IN
50/CD
%/NN
luminal/JJ
diameter/NN
considered/VBN
as/IN
significant/JJ
CAD/NN
./.
====================
On/IN
the/DT
other/JJ
side/JJ
control/NN
group/NN
have/VBP
chosen/NN
from/IN
persons/NNS
with/IN
completely/RB
normal/JJ
coronary/JJ
artery/NN
angiogram/NN
without/IN
obvious/JJ
plaque/NN
or/CC
narrowing/JJ
./.
====================
Coronary/NN
artery/NN
calcification/NN
grade/NN
2/CD
(/(
easily/RB
recognized/VBN
)/)
and/CC
3/CD
(/(
recognized/VBN
in/IN
more/RBR
than/IN
half/DT
of/IN
one/CD
coronary/JJ
artery/NN
)/)
were/VBD
included/VBN
and/CC
grade/NN
1/CD
calcification/NN
(/(
difficult/JJ
to/TO
recognize/VB
)/)
excluded/VBN
to/TO
avoid/VB
controversy/NN
./.
====================
None/NN
of/IN
the/DT
patients/NNS
had/VBD
grade/NN
4/CD
calcification/NN
./.
====================
The/DT
process/NN
of/IN
the/DT
study/NN
was/VBD
approved/VBN
by/IN
Shahid/NN
Chamran/NN
University/NN
of/IN
Ahvaz/NN
,/,
Iran/NNP
./.
====================
RNA/NN
isolation/NN
and/CC
cDNA/NN
synthesis/NN
====================
Peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
(/(
PBMC/NN
)/)
were/VBD
isolated/VBN
from/IN
the/DT
peripheral/JJ
blood/NN
of/IN
the/DT
patients/NNS
by/IN
Ficoll/NN
according/VBG
to/TO
the/DT
protocol/NN
./.
====================
Total/JJ
RNA/NN
was/VBD
isolated/VBN
from/IN
PBMC/NN
samples/NNS
using/VBG
RNX-plus/JJ
reagent/JJ
(/(
Cinnagen/NN
,/,
Tehran/NNP
,/,
Iran/NNP
)/)
following/VBG
the/DT
manufacturer/NN
’/CD
s/NNS
RNA/NN
isolation/NN
protocol/NN
./.
====================
The/DT
total/JJ
RNA/NN
yield/NN
was/VBD
determined/VBN
by/IN
gel/NN
electrophoresis/NN
and/CC
spectro-photometry/NN
./.
====================
RNAs/NNS
were/VBD
treated/VBN
with/IN
DNase/NN
(/(
SinaClone/NN
,/,
Tehran/NNP
,/,
Iran/NNP
)/)
in/IN
order/NN
to/TO
eliminate/VB
any/DT
DNA/NN
contamination/NN
./.
====================
For/IN
real-time/NN
quantitative/JJ
reverse/JJ
transcription/NN
PCR/NN
(/(
qRT-PCR/NN
)/)
,/,
RNA/NN
was/VBD
reverse/JJ
transcribed/VBN
to/TO
cDNA/NN
by/IN
using/VBG
the/DT
reverse/JJ
transcriptase/NN
enzyme/NN
./.
====================
cDNA/NN
was/VBD
synthesized/VBN
by/IN
oligo/JJ
dT/NN
and/CC
random/JJ
hexamer/NN
primer/NN
in/IN
10/CD
μL/NN
reaction/NN
from/IN
5/CD
μg/NN
RNA/NN
based/VBN
on/IN
manufacturer/NN
’/CD
s/NNS
instructions/NNS
./.
====================
Reverse/JJ
transcriptase–polymerase/NN
chain/NN
reaction/NN
====================
Reaction/NN
mixture/NN
for/IN
PCR/NN
(/(
20/CD
μL/NN
)/)
containing/VBG
1/CD
μL/NN
cDNA/NN
template/NN
,/,
500/CD
nM/NN
each/DT
of/IN
sense/JJ
and/CC
antisense/JJ
primers/NNS
that/IN
amplified/VBN
as/IN
follows/VBZ
:/:
initial/JJ
denaturation/NN
at/IN
95°C/NN
for/IN
5/CD
min/NN
,/,
and/CC
amplification/NN
by/IN
32/CD
cycles/NNS
of/IN
denaturation/JJ
at/IN
95°C/NN
for/IN
30/CD
s/NNS
,/,
annealing/VBG
at/IN
58°C/NN
for/IN
30/CD
s/NNS
,/,
and/CC
extension/NN
at/IN
72°C/JJ
for/IN
30/CD
s/NNS
followed/VBN
by/IN
5/CD
min/NN
final/JJ
extension/NN
./.
====================
The/DT
band/NN
intensity/NN
of/IN
PCR/NN
product/NN
was/VBD
verified/VBN
by/IN
electrophoresis/NN
on/IN
the/DT
agarose/NN
gel/NN
./.
====================
Agarose/DT
gel/NN
stained/VBN
with/IN
safe/JJ
stain/NN
and/CC
band/NN
density/NN
was/VBD
quantified/VBN
by/IN
UV/NN
software/NN
./.
====================
The/DT
primer/NN
sequences/NNS
are/VBP
as/IN
following/VBG
:/:
(/(
forward/IN
,/,
GTCGGAGTCAACGGATTTG/NN
;/:
reverse/JJ
,/,
TGGGTGGAATCA/NN
TATTGGA/NN
)/)
for/IN
glyceraldehyde/NN
3-phosphate/JJ
dehydrogenase/NN
(/(
GAPDH/NN
)/)
and/CC
(/(
forward/IN
,/,
AGAAAAAGCAACCACGAAGC/NN
;/:
reverse/JJ
,/,
AAACCTCTGTCTGTGAGTGCC/NN
)/)
for/IN
HOTAIR/NN
./.
====================
Statistical/JJ
analysis/NN
====================
The/DT
intensity/NN
of/IN
bands/NNS
on/IN
agarose/NN
gel/NN
was/VBD
measured/VBN
by/IN
Image/NN
J/NN
v1.51/NN
software/JJ
./.
====================
Statistical/JJ
analyses/NNS
were/VBD
made/VBN
by/IN
using/VBG
GraphPad/JJ
software/JJ
(/(
San/NN
Diego/NN
,/,
CA/NN
,/,
USA/NN
)/)
./.
====================
Comparison/NN
RNA/NN
levels/NNS
between/IN
the/DT
normal/JJ
and/CC
the/DT
patient/NN
’/CD
s/NNS
blood/NN
sample/NN
were/VBD
done/VBN
by/IN
unpaired/JJ
Student/JJ
’/CD
s/NNS
t-test/JJS
./.
====================
To/TO
examine/VB
the/DT
significance/NN
of/IN
the/DT
HOTAIR/NN
expression/NN
in/IN
CVD/NN
patients/NNS
,/,
we/PRP
tested/VBD
20/CD
blood/NN
samples/NNS
from/IN
CVD/NN
patients/NNS
and/CC
20/CD
control/NN
samples/NNS
./.
====================
The/DT
mean/JJ
age/NN
of/IN
patients/NNS
was/VBD
53.95/CD
years/NNS
at/IN
the/DT
time/NN
of/IN
CAD/NN
diagnosis/NN
and/CC
control/NN
samples/NNS
average/JJ
ages/NNS
was/VBD
50/CD
years/NNS
old/JJ
./.
====================
Size/NN
of/IN
products/NNS
for/IN
GAPDH/NN
and/CC
HOTAIR/NN
were/VBD
controlled/VBN
on/IN
2/CD
%/NN
agarose/NN
gel/NN
./.
====================
The/DT
143-bp/JJ
PCR/NN
product/NN
attributed/VBD
to/TO
amplified/VBN
GAPDH/NN
fragment/NN
was/VBD
visualized/VBN
in/IN
all/DT
the/DT
control/NN
and/CC
patient/NN
’/CD
s/NNS
samples/NNS
while/IN
19/CD
out/IN
of/IN
20/CD
of/IN
case/NN
samples/NNS
(/(
95/CD
%/NN
)/)
demonstrated/VBD
HOTAIR/NN
PCR/NN
product/NN
./.
====================
However/RB
,/,
only/RB
3/CD
normal/JJ
samples/NNS
showed/VBD
the/DT
band/NN
for/IN
HOTAIR/NN
on/IN
the/DT
agarose/NN
gel/NN
./.
====================
The/DT
results/NNS
indicated/VBD
that/IN
the/DT
expression/NN
level/NN
of/IN
HOTAIR/NN
was/VBD
higher/JJR
in/IN
CAD/NN
patients/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
compared/VBD
to/TO
non-CAD/JJ
patients/NNS
./.
====================
Unpaired/JJ
student/JJ
t-test/JJS
showed/VBD
that/IN
the/DT
relative/JJ
expression/NN
of/IN
HOTAIR/NN
in/IN
CVD/NN
patient/NN
’/CD
s/NNS
blood/NN
sample/NN
was/VBD
significantly/RB
higher/JJR
than/IN
the/DT
controls/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
(/(
fold/JJ
change/NN
,/,
4.710/CD
;/:
p/NN
</JJR
0.0001/CD
)/)
./.
====================
Also/RB
,/,
HOTAIR/NN
expression/NN
in/IN
CVD/NN
patient/NN
and/CC
control/NN
samples/NNS
were/VBD
analyzed/VBN
based/VBN
on/IN
their/PRP$
age/NN
and/CC
gender/NN
./.
====================
We/PRP
categorized/VBD
HOTAIR/NN
lncRNA/NN
expression/NN
based/VBN
on/IN
gender/NN
and/CC
age/NN
./.
====================
There/EX
were/VBD
no/DT
significant/JJ
differences/NNS
of/IN
HOTAIR/NN
expression/NN
between/IN
groups/NNS
./.
====================
CAD/NN
as/IN
one/CD
of/IN
the/DT
most/JJS
cardiovascular/JJ
disorders/NNS
is/VBZ
the/DT
main/JJ
cause/JJ
of/IN
myocardial/JJ
infarction/NN
[/(
20/CD
]/)
./.
====================
Formation/NN
of/IN
fatty/JJ
steaks/NNS
and/CC
atherosclerotic/JJ
plaques/NNS
lead/VBP
to/TO
the/DT
development/NN
of/IN
atherosclerosis/NN
[/(
21/CD
,/,
22/CD
]/)
./.
====================
Moreover/RB
,/,
different/JJ
recent/JJ
and/CC
important/JJ
discoveries/NNS
have/VBP
demonstrated/VBN
that/IN
increasing/VBG
number/NN
of/IN
ncRNAs/NNS
including/VBG
lncRNAs/NNS
and/CC
miRNAs/NNS
have/VBP
an/DT
effect/NN
on/IN
different/JJ
diseases/NNS
such/JJ
as/IN
CVDs/NNS
[/(
23/CD
,/,
24/CD
]/)
./.
====================
Discovering/VBG
the/DT
function/NN
of/IN
several/JJ
lncRNAs/NNS
in/IN
endothelial/JJ
cells/NNS
,/,
smooth/CC
muscle/NN
cells/NNS
,/,
macrophages/NNS
,/,
vascular/JJ
,/,
inflammation/NN
,/,
and/CC
metabolism/NN
have/VBP
shown/VBN
that/IN
these/DT
RNAs/NNS
can/MD
be/VB
involved/VBN
in/IN
the/DT
progression/NN
of/IN
atherosclerosis/NN
and/CC
CAD/NN
[/(
25/CD
,/,
26/CD
]/)
./.
====================
Also/RB
,/,
aberrantly/RB
expression/NN
of/IN
these/DT
ncRNAs/NNS
in/IN
CVD/NN
have/VBP
an/DT
effect/NN
on/IN
the/DT
normal/JJ
physiological/JJ
condition/NN
./.
====================
So/RB
,/,
it/PRP
seems/VBZ
that/DT
circulating/VBG
lncRNAs/NNS
have/VBP
potential/JJ
application/NN
in/IN
diagnosis/NN
and/CC
treatment/NN
of/IN
CVD/NN
[/(
27/CD
,/,
28/CD
]/)
./.
====================
Aberrant/JJ
expression/NN
of/IN
the/DT
HOTAIR/NN
has/VBZ
been/VBN
examined/VBN
in/IN
different/JJ
diseases/NNS
[/(
29/CD
]/)
./.
====================
Querying/VBG
the/DT
supplementary/JJ
data/NNS
derived/VBN
from/IN
Cai/NN
et/FW
al./FW
’/CD
s/NNS
study/NN
[/(
19/CD
]/)
shows/VBZ
that/IN
HOTAIR/NN
is/VBZ
up/RB
regulated/VBN
in/IN
CAD/NN
patients/NNS
compared/VBD
to/TO
non-CAD/JJ
patients/NNS
./.
====================
The/DT
results/NNS
have/VBP
been/VBN
achieved/VBN
by/IN
a/DT
high/JJ
throughput/NN
study/NN
./.
====================
It/PRP
motivated/JJ
us/PRP
to/TO
examine/VB
the/DT
HOTAIR/NN
expression/NN
in/IN
CAD/NN
patients/NNS
compared/VBD
to/TO
non-CAD/JJ
patients/NNS
by/IN
qRT-PCR/NN
./.
====================
Here/RB
,/,
we/PRP
found/VBD
that/IN
the/DT
expression/NN
levels/NNS
of/IN
HOTAIR/NN
were/VBD
significantly/RB
up-regulated/VBN
in/IN
patient/NN
’/CD
s/NNS
blood/NN
samples/NNS
compared/VBN
with/IN
normal/JJ
ones/NNS
./.
====================
The/DT
results/NNS
of/IN
this/DT
study/NN
demonstrate/VBP
a/DT
potential/JJ
role/NN
of/IN
the/DT
HOTAIR/NN
in/IN
CAD/NN
./.
====================
Recently/RB
,/,
HOTAIR/NN
has/VBZ
been/VBN
implicated/VBN
in/IN
CVDs/NNS
,/,
especially/RB
in/IN
aortic/JJ
valve/VBP
calcification/NN
./.
====================
Rinn/NN
et/FW
al/JJ
./.
====================
[/(
30/CD
]/)
emphasized/VBN
that/DT
HOTAIR/NN
serves/VBZ
as/IN
a/DT
scaffold/JJ
for/IN
two/CD
distinct/JJ
histone/NN
modification/NN
complexes/NNS
./.
====================
Furthermore/RB
,/,
Carrion/NN
et/FW
al/JJ
./.
====================
[/(
31/CD
]/)
found/VBN
that/IN
HOTAIR/NN
levels/NNS
are/VBP
decreased/VBN
in/IN
response/NN
to/TO
Leaflet/NN
stretch/NN
of/IN
aortic/JJ
valve/VBP
interstitial/JJ
cells/NNS
(/(
AVICs/NNS
)/)
./.
====================
Based/VBN
on/IN
the/DT
previous/JJ
studies/NNS
,/,
more/RBR
than/IN
half/NN
of/IN
the/DT
calcific/JJ
aortic/JJ
valve/VBP
display/VBP
bicuspid/JJ
morphology/NN
symptoms/NNS
./.
====================
Human/JJ
AVICs/NNS
that/DT
exposed/VBN
to/TO
stretch/VB
have/VBP
a/DT
lower/JJR
level/NN
of/IN
HOTAIR/NN
./.
====================
Reducing/VBG
the/DT
HOTAIR/NN
expression/NN
level/NN
via/IN
siRNA/JJ
was/VBD
followed/VBN
by/IN
elevated/JJ
expression/NN
of/IN
ALPL/NN
and/CC
BMP2/NN
genes/NNS
which/WDT
are/VBP
related/JJ
to/TO
calcification/NN
[/(
31/CD
]/)
./.
====================
Although/IN
Greco/NN
et/FW
al/JJ
./.
====================
[/(
32/CD
]/)
identified/VBD
HOTAIR/NN
as/IN
one/CD
of/IN
the/DT
nine/CD
lncRNAs/NNS
that/DT
are/VBP
deregulated/VBN
in/IN
heart/NN
failure/NN
[/(
32/CD
]/)
,/,
our/PRP$
results/NNS
are/VBP
inconsistent/JJ
with/IN
the/DT
data/NNS
presented/VBN
by/IN
Cai/NN
et/FW
al/JJ
./.
====================
[/(
19/CD
]/)
./.
====================
Our/PRP$
aim/NN
in/IN
this/DT
study/NN
is/VBZ
to/TO
emphasis/NN
on/IN
the/DT
enhanced/VBN
expression/NN
of/IN
circulating/VBG
HOTAIR/NN
in/IN
CAD/NN
patients/NNS
compared/VBD
to/TO
non-CAD/JJ
patients/NNS
for/IN
the/DT
first/JJ
time/NN
./.
====================
Altogether/RB
,/,
the/DT
current/JJ
study/NN
provides/VBZ
a/DT
viewpoint/NN
for/IN
further/JJ
researches/VBZ
./.
====================
More/RBR
studies/NNS
are/VBP
required/VBN
to/TO
approve/VB
the/DT
significance/NN
of/IN
HOTAIR/NN
and/CC
related/JJ
genes/NNS
as/IN
molecules/NNS
involved/VBN
in/IN
CAD/NN
./.
====================
More/RBR
experimental/JJ
studies/NNS
may/MD
reveal/VB
circulating/VBG
lncRNAs/NNS
as/IN
biomarkers/NNS
or/CC
therapeutic/JJ
targets/NNS
in/IN
CVDs/NNS
./.
====================
Reverse/JJ
transcription/NN
polymerase/NN
chain/NN
reaction/NN
analysis/NN
of/IN
the/DT
HOTAIR/NN
and/CC
GAPDH/NN
expression/NN
in/IN
the/DT
blood/NN
samples/NNS
collected/JJ
from/IN
coronary/JJ
artery/NN
disease/NN
patients/NNS
(/(
p/NN
)/)
and/CC
normal/JJ
(/(
c/NN
)/)
./.
====================
Relative/JJ
expression/NN
of/IN
the/DT
HOTAIR/NN
in/IN
patients/NNS
and/CC
normal/JJ
samples/NNS
./.
====================
t/NN
test/NN
analysis/NN
indicated/VBD
that/IN
the/DT
expression/NN
of/IN
the/DT
HOTAIR/NN
in/IN
patients/NNS
is/VBZ
significantly/RB
higher/JJR
than/IN
normal/JJ
(/(
****p/JJ
</JJR
0.0001/CD
for/IN
HOTAIR/NN
)/)
./.
====================
CAD/NN
,/,
coronary/JJ
artery/NN
disease/NN
./.
====================
Age/NN
and/CC
sex/NN
distribution/NN
of/IN
the/DT
samples/NNS
(/(
n/NN
=/JJ
20/CD
in/IN
each/DT
group/NN
)/)
====================
